Updated: 8/11/2011 1:15 p.m.
Kidney care services provider DaVita Inc. (NYSE:DVA) is taking on the environmental footprint left by its customers by launching a pilot program to recycle some of the waste from dialysis centers.
The Medical Device Business Journal — Medical Device News & Articles | MassDevice
Updated: 8/11/2011 1:15 p.m.
Kidney care services provider DaVita Inc. (NYSE:DVA) is taking on the environmental footprint left by its customers by launching a pilot program to recycle some of the waste from dialysis centers.
Fresenius Medical Care AG (NYSE:FMS) had an active day on the M&A trail, announcing two deals worth a combined $2.1 billion that should bolster the company’s presence in the U.S.
The German dialysis giant, which houses its U.S. headquarters in Waltham, Mass., said it will pay $1.7 billion to acquire Liberty Dialysis Holdings Inc., a privately held company out of Mercer Island, Washington, which was owned by two private equity firms KRG Capital Partners and Bain Capital.
Shares of NxStage Medical, Inc. (NASDAQ:NXTM) jumped by more than 12 percent through midday trading on Wall Street today, as the company reported a 22 percent jump in sales during the second quarter and upped its 2011 top line guidance.
NXTM posted $53.7 million in sales during the three month period ended on June 30, 2011, compared to $44 million during the same period last year. The strong sales helped the company narrow its net losses to $5.3 million, compared to $8.1 million for the same period last year.
Fresenius Medical Care AG (NYSE:FMS) had an active day on the M&A trail, announcing two deals worth a combined $2.1 billion that should bolster the company’s presence in the U.S.
The German dialysis giant, which houses its U.S. headquarters in Waltham, Mass., said it will pay $1.7 billion to acquire Liberty Dialysis Holdings Inc., a privately held company out of Mercer Island, Washington, which was owned by two private equity firms KRG Capital Partners and Bain Capital.
NxStage Medical Inc. (NSDQ:NXTM) is poised to take a $1 billion bite out of the dialysis market as it drives its share from 1 percent of dialysis patients into double-digit range, according to a Wall Street analyst.
After meeting with the Lawrence, Mass.-based company’s CEO Jeffrey Burbank and investor relations VP Kristen Sheppard last week, Leerink Swann’s Danielle Antalffy wrote in a note to investors that NXTM stock is a smart buy these days.
The gold standard in long-term glucose monitoring for patients with diabetes proved to be of limited value in dialysis patients, according to a new study at Wake Forest Baptist Medical Center.
Although the American Diabetes Association has deemed the HbA1c test an effective tool for diagnosing diabetes, kidney doctors recently determined that the HbA1c is not as useful for managing patients with diabetes and advanced kidney failure.
NxStage Medical Inc. (NASDAQ:NXTM) will not renew one of its key supplier agreements for the blood tubing sets distributed by its Medisystems subsidiary.*
The Lawrence, Mass.-based renal products maker said that it will let a deal with Kawasumi Laboratories Inc. expire Jan. 31, 2012. The Japanese company is the “only supplier of needles and certain blood tubing sets that we sell to our customers,” NxStage officials said in a regulatory filing.
NxStage Medical Inc. (NASDAQ:NXTM) handed out pay raises to several members of its leadership team after a year that saw the dialysis maker boost sales 20 percent and cut its net losses.